MEDNAX (MD) Misses Q4 EPS by 4c ; Provides Outlook

MEDNAX (NYSE: MD) reported Q4 EPS of $0.50, $0.04 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $494 million versus the consensus estimate of $486.23 million.

Preliminary 2026 Outlook

On a preliminary basis, Pediatrix anticipates that its 2026 Adjusted EBITDA, as defined above, will be in a range of $280 million to $300 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
• Are we witnessing a fundamental or speculative rally in the S&P 500?